Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Pancreatic Cancer and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3263
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Pancreatic Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Pancreatic Cancer and Peptides.

    To find out more about Triple Analysis: Leukemia, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
7TM Pharma
AB Science
Abbott
Abiogen
Acceleron Pharma
Actinium Pharmaceuticals
Active Biotech
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Allostera
Allosterix
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Arca biopharma
Ardana
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Baxter International
Bayer
Betapharma
Bio-Path Holdings
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Bionovo
BioNumerik
BioSante
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Choongwae
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
CompleGen
Compugen
Cornerstone Pharmaceuticals
CritiTech
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Digna Biotech
Dong-A
Dongkook Pharm
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
FibroGen
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GlycoMimetics
GP Pharm
Gryphon Therapeutics
Hanmi
Hayashibara
Heber Biotec
Hoffmann-La Roche
Human Genome Sciences
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
Innovive
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
Kadmon
KAEL-GemVax
KaloBios
Kanisa
Karyon-CTT
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
Protagonist
Protgen
Q Chip
QLT
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
Shenogen
Shire
Sidus
Soligenix
Southern Research Institute
Spectrum Pharmaceuticals
Spirogen
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Trion Pharma
UMN Pharma
Unigene
United Biomedical
Valeant
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
XBiotech
Xencor
Xerion
Xigen
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zelos Therapeutics
Zensun
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
aflibercept
AGS-1C4D4
alemtuzumab
amonafide malate
amsacrine
angiopep+paclitaxel
apricoxib
ARC-100
ARQ-197
barasertib
bardoxolone methyl
belinostat
bevacizumab
bisantrene
bosutinib
brivanib alaninate
brivudine
Cabozantinib
capecitabine
catumaxomab
CBP-501
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
clofarabine
conatumumab
corticorelin acetate
CPI-613
CRLX-101
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dalotuzumab
dasatinib
daunorubicin
decitabine
deslorelin
docetaxel
doxorubicin
E-75
E-7820
elacytarabine
emepepimut-S
eniluracil
enocitabine
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
FPI-01
ganitumab
gefitinib
gemtuzumab ozogamicin
goserelin
GSK-1120212
GV-1001
GVAX
GX-301
Her-2/Neu peptides
histamine dihydrochloride
histrelin
icotinib hydrochloride
idarubicin
imatinib mesilate
imMucin
IMP-321
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ISA-P53-01
kahalalide F
KD032
L19-IL2
lanreotide
lapatinib ditosylate
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LipoVIL12
lumiliximab
masitinib
MDX-1379
MetXia
midostaurin
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
nadroparin
NAFB001
netupitant
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
olaparib
ON-01910
OTS-102
ozarelix
P-276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
pentostatin
perifosine
plitidepsin
polyclonal antibody stimulator
PX-12
razoxane
Rexin-G
rhIFN-alpha
rindopepimut
rituximab
romidepsin
romurtide
RX-0201
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Survivac
talminogene laherparepvec
tamibarotene
tegafur + uracil
temsirolimus
teniposide
thymalfasin
tigatuzumab
tipifarnib
TM-30339
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vapreotide, immediate-release
varlitinib
vismodegib
vitespen
volociximab
vosaroxin
VX-001
WX-671
Z-360
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Pancreatic Cancer and Peptides.
    To find out more about Triple Analysis: Leukemia, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Leukemia and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Pancreatic Cancer. Learn More


Triple Analysis: Leukemia, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More